Current approaches in CRISPR-Cas system for metabolic disorder

Area of Science:

• Genomic Medicine
• Biotechnology

Background:

• CRISPR-Cas technology revolutionizes genomic medicine, offering novel therapeutic avenues for metabolic disorders.
• Metabolic diseases, often with complex genetic underpinnings, present significant treatment challenges.

Purpose of the Study:

• To review recent advancements in CRISPR-Cas systems and stem cell therapy for metabolic disease treatment.
• To explore the foundational mechanisms and applications of CRISPR-Cas technology in gene editing for metabolic disorders.

Main Methods:

• Utilizing CRISPR/Cas9-mediated gene therapy with viral vectors in preclinical models.
• Employing high-throughput CRISPR screens for identifying novel genes and pathways in metabolic dysfunction.
• Integrating CRISPR-Cas technology with stem cell therapy for genetic correction and cellular regeneration.

Main Results:

• Demonstrated potential of CRISPR-Cas in preclinical models of hypercholesterolemia, glycogen storage diseases, and phenylketonuria.
• Identified new therapeutic targets and pathways through CRISPR screening for metabolic diseases.
• Showcased the synergistic effects of combining CRISPR-Cas with stem cell therapy for enhanced treatment outcomes.

Conclusions:

• CRISPR-Cas technology, particularly when combined with stem cell therapy, represents a significant breakthrough in treating metabolic diseases.
• These integrated approaches offer promising prospects for effective and potentially curative therapies for a range of metabolic disorders.
• Further research and application of CRISPR-Cas systems hold potential for advancing genetic correction and regenerative medicine in metabolic health.